<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0146)http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/endocrine_disorders.html/0601/0601_q6/0601_i2?fn=document-frame.htm&f=templates -->
<HTML><HEAD><TITLE>Clinical Evidence</TITLE>
<META http-equiv=Content-Type content="text/html; charset=windows-1252"><LINK 
href="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/bmj.css" type=text/css rel=stylesheet>
<META content="MSHTML 5.50.4807.2300" name=GENERATOR></HEAD>
<BODY topMargin=0>
<TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/0601_i2.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Endocrine disorders</SECTION></SPAN><IMG 
            height=10 src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR>
            <SPAN class=localhead 
            id=localhead><TOPIC>Cardiovascular disease in diabetes</TOPIC><IMG 
            height=10 src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/spacer.gif" width=10 align=absMiddle 
            border=0></SPAN></TD>
        </TR>
        <TR>
          <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30>Ronald Sigal <SPAN 
            style="FONT-WEIGHT: bold; BACKGROUND: #ffffff">and</SPAN> Janine Malcolm<IMG height=10 
            src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/spacer.gif" width=10 align=absMiddle 
        border=0></TD>
        </TR></TBODY></TABLE><BR>
      <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Antihypertensives</H1>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question>&nbsp;<B>What are the effects of antihypertensive 
            drugs in people with diabetes?</B></TD>
        </TR></TBODY></TABLE><BR><A 
      name=I2>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Which antihypertensive 
        is best in diabetes?</H2>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>Different antihypertensive 
      drugs</B></TD></TR></TBODY></TABLE></A>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR>
          <TD><A name=I2-SUMSTATEMENT><B>
            <P style="MARGIN-LEFT: 3px" align=justify><IMG 
            alt="substantive change" src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/smalrght.gif" 
            border=0>One systematic review of large RCTs has found that ACEinhibitors 
              versus calcium channel blockers as initial therapy for hypertension 
              significantly reduce cardiovascular events in people with type 2 
              diabetesaged 50–65 years. We found no clear evidence directly comparing 
              ACEinhibitors anddiuretics. One large RCT found that an ACEinhibitor 
              versus a ß blocker had similar effect on cardiovascular events.<IMG 
            alt="substantive change" src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/smalleft.gif" 
            border=0> One large RCT has found that doxazosin (an &#945; blocker) 
              versus chlorthalidone (a diuretic) increases the risk of congestive 
              heart failure.</P>
            </B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A 
            name=I2-BENEFITS><B>Benefits: </B></A></FONT><IMG 
            alt="substantive change" src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/smalrght.gif" 
            border=0>We found one systematic review (search date 2000, 4 RCTs, 
              2180 people with diabetes) <A 
            href="#references">[24]</A> andtwo subsequent RCTs. <A 
            href="#references">[25]</A> <A 
            href="#references">[26]</A> The systematic review compared inhibitors 
              (1133 people) versus other antihypertensive drugs (diuretics, ß 
              blockers, or calcium channel blockers; 1047 people). <A 
            href="#references">[24]</A> <B>ACE inhibitors versus calcium channel 
              blockers:</B> We found one systematic review, <A 
            href="#references">[24]</A> which found two RCTs <A 
            href="#references">[27]</A> <A 
            href="#references">[28]</A> comparing ACE inhibitors versus calcium 
              channel blockers in people with diabetes, and one subsequent RCT 
              <A 
            href="#references">[25]</A> comparing ACE inhibitors versus calcium 
              channel antagonists versus conventional treatment (ß blockers or 
              hydrochlorothiazide plus amiloride). The two RCTs in the systematic 
              review found that ACE inhibitors versus calcium channel blockers 
              significantly reduced cardiovascular events (34/424 [8%] with ACE 
              inhibitor <EM>v</EM> 151/526 [16%] with calcium channel blocker; 
              ARR 8%, 95% CI 4% to 13%; RR 0.49, 95% CI 0.33 to 0.72; NNT 13, 
              95% CI 7 to 25). ACE inhibitors versus calcium channel blockers 
              also reduced the three outcomes of death, AMI, and stroke, but the 
              reductions were not significant.<IMG 
            alt="substantive change" src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/Diabetes_and_ACE_CE_content_files092101/0601_i2_files/smalleft.gif" 
            border=0> The subsequent RCT (6614 people, 719 with diabetes, mean 
              age 76 years, mean blood pressure 190/99&nbsp;mmHg) found (among 
              the subgroup of people with diabetes) no significant difference 
              in the incidence of major cardiovascular events over 4 years (64.2 
              events/1000 person years with ACE inhibitors <EM>v</EM> 67.7 with 
              calcium antagonists <EM>v</EM> 75.0 with conventional agents). <A 
            href="#references">[25]</A> <B>ACE inhibitors versus diuretics: </B>We 
              found one systematic review, <A 
            href="#references">[24]</A> which found no RCTs specifically comparing 
              ACE inhibitors versus diuretics in people with diabetes, but found 
              one RCT (572 people, 6.1 years) comparing ACE inhibitors versus 
              alternative treatment that included ß blockers, combination ß blockers 
              and diuretics, and diuretics in people with and without diabetes. 
              Fewer people allocated to captopril experieinced AMI, stroke or 
              death compared to diuretics or ß blockers (43/263 [18%] with diuretics/ß 
              blockers <EM>v </EM>30/309 [10%] with captopril; ARR 6.6%, 95 CI 
              1.1% to 12.2%; NNT 15). <A 
            href="#references">[24]</A> <B>ACE inhibitors versus ß blockers:</B> 
              We found one systematic review, which included one RCT (758 people, 
              456 cardiovascular events) comparing an ACE inhibitor (captopril) 
              versus a ß blocker (atenolol) over 8.4 years. <A 
            href="#references">[29]</A> The RCT found that captopril versus atenolol 
              did not significantly reduce the number of cardiovascular events 
              (102/400 [25.5%] with captopril <EM>v</EM> 75/358 [20.9%] with atenolol; 
              ARI +5%, 95% CI –1% to +11%; RR 1.22, 95% CI 0.94 to 1.58). <B>Other 
              comparisons: </B>We found no systematic review but found one RCT 
              <A 
            href="#references">[26]</A> (age <U>&gt;</U>&nbsp;55 years, with hypertension 
              and either previous CVD or at least 1 additional CVD risk factor) 
              comparing chlorthalidone, doxazosin, amlodipine, and lisinopril. 
              After 3.3 years of follow up there was no difference between doxazosin 
              (3183 people with diabetes) and chlorthalidone (5481 people) in 
              the primary outcome (fatal coronary heart disease [CHD] or non-fatal 
              AMI), but the doxazosin arm was terminated because of an excess 
              risk of combined CVD events (coronary heart disease death, non-fatal 
              AMI, stroke, revascularisation procedures, angina, congestive heart 
              failure, and peripheral vascular disease) compared with chlorthalidone 
              (OR 1.24, 95% CI 1.12 to 1.38). The RCT is still in progress. <A 
            href="#references">[26]</A> </P>
          </TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I2-HARMS><B>Harms: </B></A></FONT>In 
              one RCT, people taking atenolol gained more weight than those taking 
              captopril (3.4&nbsp;kg with atenolol <EM>v</EM> 1.6&nbsp;kg with 
              captopril, P&nbsp;=&nbsp;0.02). <A 
            href="#references">[29]</A> Over the first 4 years of the trial, people 
              allocated to atenolol had higher mean HbA1c (7.5% <EM>v</EM> 7.0%, 
              P&nbsp;=&nbsp;0.004),<B> </B>but there was no difference between 
              groups over the subsequent 4 years. There was no difference between 
              atenolol and captopril in rates of hypoglycaemia, lipid concentrations, 
              tolerability, blood pressure lowering, or prevention of disease 
              events.</P>
          </TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I2-COMMENT><B>Comment: 
              </B></A></FONT>We found evidence that ACE inhibitors are superior 
              to calcium channel blockers as initial therapy. We found no clear 
              evidence directly comparing ACE inhibitors and diuretics. It is 
              unclear whether ACE inhibitors or ß-blockers are superior to each 
              other. In most trials, combination therapy with more than one agent 
              was required to achieve target blood pressures.</P>
          </TD></TR></TBODY></TABLE><BR><A 
      name=references></A>
      <TABLE cellSpacing=0 cellPadding=0 border=0>
        <TBODY>
        <TR>
          <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
          <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD></TR>
        <TR>
          <TD class=key-message id=key-message width=90 
            bgColor=#404040><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE cellPadding=2 width="100%" align=center>
        <TBODY>
        <TR><A class=reference id=reference name=REF24></a>
          <TD class=reference id=reference vAlign=top width=15>24. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Pahor M, Psaty 
            BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic 
            benefits of ACE inhibitors and other antihypertensive drugs in patients 
            with type 2 diabetes. <EM>Diabetes Care</EM> 2000;23:888–892. Search 
            date January 2000; primary source Medline.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF25></a>
          <TD class=reference id=reference vAlign=top width=15>25. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Lindholm 
            LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive 
            treatment in preventing cardiovascular events in elderly diabetic 
            patients: results from the Swedish trial in old patients with 
            hypertension–2. <EM>J Hypertens</EM><B> </B>2000;18:1671–1675.</TD></TR>
        <TR><A class=reference id=reference name=REF26></a>
          <TD class=reference id=reference vAlign=top width=15>26. </TD>
          <TD class=reference id=reference vAlign=top width="100%">ALLHAT Collaborative 
            Research Group. Major cardiovascular events in hypertensive patients 
            randomised to doxazosin vs chlorthalidone: the antihypertensive and 
            lipid-lowering treatment to prevent heart attack trial (ALLHAT). <EM>JAMA</EM> 
            2000;283:1967–1975. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF27></a>
          <TD class=reference id=reference vAlign=top width=15>27. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Estacio RO, 
            Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared 
            with enalapril on cardiovascular events in patients with non-insulin-dependent 
            diabetes and hypertension. <EM>N Engl J Med</EM> 1998;338:645–652. 
          </TD>
        </TR>
        <TR><A class=reference id=reference name=REF28></a>
          <TD class=reference id=reference vAlign=top width=15>28. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Tatti P, Pahor 
            M, Byington RP, et al. Outcome results of the Fosfinopril versus Amlodipine 
            Cardiovascular Events randomised Trial (FACET) in patients with hypertension 
            and NIDDM. <EM>Diabetes</EM><EM>Care</EM> 1998;21:597–603.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF29></a>
          <TD class=reference id=reference vAlign=top width=15>29. </TD>
          <TD class=reference id=reference vAlign=top width="100%">UK Prospective 
            Diabetes Study Group. Efficacy of atenolol and captopril in reducing 
            risk of macrovascular and microvascular complications in type 2 diabetes: 
            UKPDS 39. <EM>BMJ</EM> 1998;317:713–720. </TD>
        </TR></TBODY></TABLE>
      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
          <TD align=right width="50%"><IMG 
            alt="BMJ - Clinical Evidence" src="file:///W|/ATHENADSS/doc/ATHENA/Clinical%20Evidence/ce-bmj-small-banner%5B1%5D.gif" 
            border=0 width="89" height="44"></TD>
        </TR>
        <TR>
          <TD align=left width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">Issue 5 - June 
          2001</SPAN></TD>
          <TD align=right width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</SPAN></TD>
        </TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0601.PDF"; 
</SCRIPT>
      </TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT type=hidden value=56 name=LPHitCount> 
</FORM></BODY></HTML>
